IP Library › Granted Patent US 12,618,071
Granted Patent B2
US 12,618,071 · App. 17/985,005 · Granted May 5, 2026

Multimeric oligonucleotides with divided strands

Inventor: Jonathan Miles Brown (Silver Spring, MD)
Assignee: MPEG LA, L.L.C.
C12N15/1137C12N15/113C12N2310/14C12N2310/314C12N2310/321C12N2310/51C12N2330/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,618,071
App. No.
17/985,005
Granted
May 5, 2026
Kind
B2
Abstract

The present disclosure relates to multimeric oligonucleotides comprising subunits, each of the subunits independently comprises a single-stranded or double-stranded oligonucleotide. Each of the subunits is joined to another subunit by a covalent linker, and at least one subunit comprises at least one partial single-stranded oligonucleotide. The present disclosure also relates to methods of synthesizing the multimeric oligonucleotides and the methods of using the multimeric oligonucleotides disclosed herein.

Claims (23)

1 . A multimeric oligonucleotide comprising Structure 6:

wherein:

each is a single-stranded oligonucleotide, wherein each single-stranded oligonucleotide is 10-28 nucleotides in length;

each is a partial single-stranded oligonucleotide, wherein each partial single-stranded oligonucleotide is 5-14 nucleotides in length;

each • is a covalent linker;

each is a complementary strand; and

each of a, b, c, d, e, f, g, h, i, j, and k is independently an integer greater than or equal to zero, with the proviso that at least one of c, e, h, and j is greater than or equal to 1.

2 . The multimeric oligonucleotide of claim 1 , wherein the multimeric oligonucleotide comprises Structure 7:

wherein:

m and n are each independently an integer greater than or equal to 1; and

o is an integer greater than or equal to 0.

3 . The multimeric oligonucleotide of claim 2 , wherein the multimeric oligonucleotide comprises one of the following structures:

4 . The multimeric oligonucleotide of claim 1 , wherein each subunit in the multimeric oligonucleotide is RNA, DNA, or an artificial or non-natural nucleic acid analog.

5 . The multimeric oligonucleotide of claim 1 , wherein at least one subunit is a single-stranded subunit.

6 . The multimeric oligonucleotide of claim 5 , wherein the at least one single-stranded subunit is an antisense oligonucleotide.

7 . The multimeric oligonucleotide of claim 1 , wherein at least one covalent linker • is a cleavable covalent linker.

8 . The multimeric oligonucleotide of claim 7 , wherein the cleavable covalent linker comprises an acid cleavable bond, a reductant cleavable bond, a bio-cleavable bond, or an enzyme cleavable bond.

9 . The multimeric oligonucleotide of claim 1 , wherein each covalent linker • is the same.

10 . The multimeric oligonucleotide of claim 1 , wherein at least one covalent linker • is different from the other covalent linkers.

11 . The multimeric oligonucleotide of claim 1 , at least two subunits are joined by a covalent linker • between the 3′ end of a first subunit and the 3′ of a second subunit.

12 . The multimeric oligonucleotide of claim 1 , wherein at least two subunits are joined by a covalent linker • between the 5′ end of a first subunit and the 5′ of a second subunit.

13 . A composition comprising the multimeric oligonucleotide of claim 1 and a pharmaceutically acceptable excipient.

14 . The multimeric oligonucleotide of claim 1 , wherein the single-stranded oligonucleotide is a RNA.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2022
From: BROWN, JONATHAN MILES
To: MPEG LA, L.L.C.
Reel/Frame 061743/0031 →
Continuity (3)
Continuation 17922254
Provisional Application 63018406 · Apr 30, 2020
Related Publication 20230146956A1 · May 11, 2023
References Cited (125)
US 5552535A · McLean et al. · 1996 [cited by applicant]
US 8106173B2 · Kandimalla et al. · 2012 [cited by applicant]
US 8110674B2 · Manoharan et al. · 2012 [cited by applicant]
US 8188261B2 · Kandimalla et al. · 2012 [cited by applicant]
US 8362233B2 · Kandimalla et al. · 2013 [cited by applicant]
US 8431544B1 · Agrawal et al. · 2013 [cited by applicant]
US 8580946B2 · Park et al. · 2013 [cited by applicant]
US 8759310B2 · Kandimalla et al. · 2014 [cited by applicant]
US 9243050B2 · Kandimalla et al. · 2016 [cited by applicant]
US 9255269B2 · Park et al. · 2016 [cited by applicant]
US 9616085B2 · Hong et al. · 2017 [cited by applicant]
US 9644209B2 · Park et al. · 2017 [cited by applicant]
US 10597659B2 · Park et al. · 2020 [cited by applicant]
US 11078484B2 · Brown et al. · 2021 [cited by applicant]
US 11352629B2 · Hadwiger et al. · 2022 [cited by applicant]
US 11767531B2 · Hadwiger · 2023 [cited by examiner]
US 11859184B2 · Park et al. · 2024 [cited by applicant]
US 20040235773A1 · Zhao et al. · 2004 [cited by applicant]
US 20070287681A1 · Jeong et al. · 2007 [cited by applicant]
US 20080108801A1 · Manoharan et al. · 2008 [cited by applicant]
US 20080214436A1 · Yu et al. · 2008 [cited by applicant]
US 20080287383A1 · Quay et al. · 2008 [cited by applicant]
US 20080311040A1 · Berry et al. · 2008 [cited by applicant]
US 20090126038A1 · Van De Craen et al. · 2009 [cited by applicant]
US 20130330293A1 · Long et al. · 2013 [cited by applicant]
US 20140194610A1 · Verdine et al. · 2014 [cited by applicant]
US 20150197754A9 · Park et al. · 2015 [cited by applicant]
US 20150299695A1 · Uhlmann et al. · 2015 [cited by applicant]
US 20150315585A1 · Uhlmann et al. · 2015 [cited by applicant]
US 20160193354A1 · Noe et al. · 2016 [cited by applicant]
US 20160298124A1 · Borodovsky et al. · 2016 [cited by applicant]
US 20160347780A1 · Wada et al. · 2016 [cited by applicant]
US 20170189525A1 · Brunskill et al. · 2017 [cited by applicant]
US 20170204408A9 · Lewis · 2017 [cited by applicant]
US 20170349896A1 · Albaek et al. · 2017 [cited by applicant]
US 20180080028A1 · Park et al. · 2018 [cited by applicant]
US 20180312839A1 · Bhat et al. · 2018 [cited by applicant]
US 20190062743A1 · Uhlmann et al. · 2019 [cited by applicant]
US 20190085331A1 · Hadwiger et al. · 2019 [cited by applicant]
US 20200239892A1 · Park et al. · 2020 [cited by applicant]
US 20200308578A1 · Woolf et al. · 2020 [cited by applicant]
US 20210380979A1 · Brown et al. · 2021 [cited by applicant]
US 20230114023A1 · Brown et al. · 2023 [cited by applicant]
US 20230220388A1 · Brown · 2023 [cited by applicant]
US 20230279390A1 · Brown · 2023 [cited by applicant]
US 20230287406A1 · Brown · 2023 [cited by examiner]
EP 2395085A2 · 2011 [cited by applicant]
JP 2009502198 · 2009 [cited by applicant]
JP 2014527819 · 2014 [cited by applicant]
JP 2015529469 · 2015 [cited by applicant]
JP 2017565893A · 2018 [cited by applicant]
JP 2011518784 · 2019 [cited by applicant]
KR 1020100089796 · 2010 [cited by applicant]
KR 1020110083919A · 2011 [cited by applicant]
WO WO2004030634A2 · 2004 [cited by applicant]
WO WO2004090108A2 · 2004 [cited by applicant]
WO WO2004091515A2 · 2004 [cited by applicant]
WO WO2004094345A2 · 2004 [cited by applicant]
WO WO2004094595A2 · 2004 [cited by applicant]
WO WO2007117686A2 · 2007 [cited by applicant]
WO WO2008109105A2 · 2008 [cited by examiner]
WO WO2009014887A2 · 2009 [cited by applicant]
WO WO2009126933A2 · 2009 [cited by applicant]
WO WO2010021720A1 · 2010 [cited by applicant]
WO WO2011031520A1 · 2011 [cited by applicant]
WO WO2011109380A1 · 2011 [cited by applicant]
WO WO2011132672 · 2011 [cited by applicant]
WO WO2013040429A1 · 2013 [cited by applicant]
WO WO2014043544A1 · 2014 [cited by examiner]
WO WO2014208973 · 2014 [cited by applicant]
WO WO2019105421A1 · 2019 [cited by applicant]
WO WO2021222635A2 · 2021 [cited by applicant]
WO WO2021236689A1 · 2021 [cited by applicant]
U.S. Appl. No. 17/922,254 (Year: 2022). [cited by examiner]
U.S. Appl. No. 17/747,924 (Year: 2022). [cited by examiner]
Dubiley et al (Nucleic Acids Res., vol. 25, No. 12, pp. 2259-2265 (1997)). [cited by examiner]
Parinov et al (Nucleic Acids Res., vol. 24, No. 15 (1996). [cited by examiner]
Bui et al (New J. Phys., vol. 19, Pub. No. 015006, pp. 1-10 (2017)) (Year: 2017). [cited by examiner]
Bordoni et al (Nucleic Acids Res., vol. 30, No. 8e34, pp. 1-7 (2002)) (Year: 2002). [cited by examiner]
Lee et al (Biomaterials, vol. 32, pp. 2359-2368 (2011)) (Year: 2011). [cited by examiner]
Yoo et al (Chem. Commun., vol. 50, pp. 6765-6767 (2014)) (Year: 2014). [cited by examiner]
Mok et al (Nature Materials, vol. 9, pp. 272-278 (2010) (Year: 2010). [cited by examiner]
Roberts et al (Nature Rev., Drug Discovery, vol. 19, pp. 673-694 (2020)) (Year: 2020). [cited by examiner]
Osborn et al (Nucleic Acid Therapeutics, vol. 28, No. 3, pp. 128-136 (2018)) (Year: 2018). [cited by examiner]
Damase et al (Frontiers in Bioengineering and Biotechnology, vol. 9, Article 628137, pp. 1-24 (2021)) (Year: 2021). [cited by examiner]
Bost et al (ACS Nano, vol. 15, pp. 13993-14021 (2021)) (Year: 2021). [cited by examiner]
Bordoni et al., “Investigation of the multiple anchors approach in oligonucleotide microarray preparation using linear and stem-loop structured probes”, Nucleic Acids Research, Apr. 15, 2002, vol. 30, No. 8, article e34… [cited by applicant]
Bui et al., “Design and analysis or linear cascade DNA hybridization chain reactions using DNA hairpins”, New Journal or Physics, 2017, vol. 19, article 015006; pp. 1-10. [cited by applicant]
Choi et a, “Next-Generation in Situ Hybridization Chain Reaction: Higher Gain, Lower Cost, Greater Durability”, ACS Nano, May 27, 2014, vol. 8, No. 5, pp. 4284-4294. [cited by applicant]
Dubiley et al., “Fractionation, phosphorylation and ligation on oligonucleotide microchips to enhance sequencing by hybridization”, Nucleic Acids Research, Jun. 15, 1997, vol. 25, No. 12; pp. 2259-2265. [cited by applicant]
Parinov et al., “DNA sequencing by hybridization to microchip octa-and decanucleotides extended by stacked pentanucleotides”, Nucleic Acids Research, 1996, vol. 24, No. 15, pp. 2998-3004. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2021/029984, mailing date Nov. 10, 2021, in 16 pages. [cited by applicant]
Bolcato-Bellemin et al. (2007), “Sticky overhangs enhance siRNA-mediated gene silencing,” Proc. Natl. Acad. Sci. USA, 104:41: 16050-16055. [cited by applicant]
Bonger, K. M., “Dimeric ligands for GPCRs involved in human reproduction: synthesis and biological evaluation” pp. 1-217, Dec. 19, 2008. [cited by applicant]
Brown, JM et al., Ligan Conjugated Multimeric siRNAs Enable Enhanced Uptake and Multiplexed Gene Silencing. Nucieic Acid Therapeutics, Sep. 26, 2019, vol. 29, No. 5, pp. 231-244; entire document. DOI: 10.1089/nat.2019.0… [cited by applicant]
Cellamare et al., “Design, synthesis, and biological evaluation of glycine-based molecular tongs as inhibitors of AB1-40 aggregation in vitro”, Bioorganic & Medicinal Chemistry, vol. 16, 2008, pp. 4810-4822. [cited by applicant]
Elbashir et al. (2001), “Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells,” Nature, 411: 494-498. [cited by applicant]
Gary et al. (2007), “Polymer-based siRNA delivery: Perspective on the fundamental and phenomenological distinctions from polymer-based DNA delivery,” J. Controlled Release, 121: 64-73. [cited by applicant]
Hong et al., “Gene Silencing by siRNA Microhydrogels via Polymeric Nanoscale Condensation”, Aug. 2011, JAGS, 133: 13914-13917. [cited by applicant]
Jeong, J.H., et al., siRNA conjugate delivery systems. Bioconjug Chem. Jan. 2009;20(1):5-14. doi: 10.1021/bc800278e. [cited by applicant]
Kang et al. “HER2 RNA Aptamerand Cell Penetrating Peptide-Mediated Delivery of Multimeric Antisense Strands of siRNAs for Gene Silencing: Multimeric antisense strands of siRNAS”, bull. Korean chem. Soc., vol. 37, No. 9,… [cited by applicant]
Kashihara et al., “Analysis of Renal Microcirculation and Permeability-Change with Bio-Imaging Techniques”, KENBIKYO, 2011, vol. 46, No. 3, p. 181-187. [cited by applicant]
Kim, S.H., et al., Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J Control Release. Jul. 14, 2008;129(2): 107-16. doi: 10.1016/j.jconrel.2008.03.008.… [cited by applicant]
Kim, S.H., et al., LHRH receptor-mediated delivery of siRNA using polyelectrolyte complex micelles self-assembled rom siRNA-PEG-LHRH conjugate and PEI. Bioconjug Chem. Nov. 19, 2008; 19(11):2156-62. doi: 10.1021/bc80024… [cited by applicant]
Kim et al. (2006) “PEG conjugated VEGF siRNA for anti-angiogenic gene therapy,” Journal of Controlled Release, 116:123-129. [cited by applicant]
Lee et al., (2012) “Molecularly Self-Assembled Nucleic-Acid Nanoparticles for Targeted in Vivo siRNA Delivery,” Nature Nanotechnology, 7(6):389-393. [cited by applicant]
Lee et al., (2012) “Small-Interfering RNA (siRNA)-Based Functional Micro-and Nanostructures for Efficient and Selective Gene Silencing,” Accounts of Chemical Research, 45(7):1014-1025. [cited by applicant]
Mok et al., “Self-crosslinked and reducible fusogenic peptides for intracellular delivery of siRNA”, Biopolymers. J008 Ocl;89(10):881-8. doi: 10.1002/bip.21032. [cited by applicant]
Moschos, S.A, et al., Lung delivery studies using siRNA conjugated to TAT(48-60) and penetralin reveal peptide nduced reduction in gene expression and induction of innate immunity. Bioconjug Chem. Sep.-Oct. 2007;18(5):1… [cited by applicant]
Motoyashi et al., “Glomerular Disease and tubule injury”, Japanese Journal of Pediatric Nephrology, 2009, vol. 22, No. 2, p. 76-81. [cited by applicant]
Muratovska, A., et al., Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett. Jan. 30, 2004;558(1-3):63-8. [cited by applicant]
Rinsho Yakuri, Japanese Journal of Clinical Pharmacology and Therapeutics, 2016, vol. 47, No. 2, p. 56-61. [cited by applicant]
Schiffelers RM, et al. “Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle”, Nucleic Acids Res. 32 (2004) e149. Published Oct. 1, 2004. [cited by applicant]
Subramanian et al., “Enhancing Antisense Efficacy with Multimers and Multi-Targeting Oligonucleotides (MTOs) Using Cleavable Linkers,” Nucleic Acids Research, Oct. 7, 2015, vol. 43, Issue 19, pp. 9123-9132. [cited by applicant]
Sugo, T. et al., Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles, Journal of Controlled Release, 237 (2016) 1-13. [cited by applicant]
Sun et al., (1997) “Synthesis of 3′-thioribonucleosides and their incorporation into oligoribonucleotides via phosphoramidite chemistry,” RNA, 3(11 ):1352-63. [cited by applicant]
Tai, Wanyi, Bin Qin, and Kun Cheng. “Inhibition of breast cancer cell growth and invasiveness by dual silencing of HER-2 and VEGF.” Molecular pharmaceutics 7.2 (2010): 543-556. [cited by applicant]
Xu, et al., “Delivery systems for siRNA drug development in cancer therapy”, Asian Journal of Pharmaceutical Sciences, Aug. 28, 2014, vol. 10, No. 1, pp. 1-12. [cited by applicant]
Zhang et al., “Synthesis and Biological Evaluation of Bivalent Ligands for the Cannabinoid 1 Receptor” Journal of Medicinal Chemistry, 53, pp. 7048-7060. [cited by applicant]
Office Action with English translation in Japanese application No. 2022-564505, dated Dec. 18, 2023, in 12 pages. [cited by applicant]
Heissig et al., “DNA as tunable adaptor for siRNA Polyplex Stabilization and Functionalization”, Molecular Therapy-Nucleic Acids, vol. 5(3):e288 (2016). [cited by applicant]
Office Action in Canadian application No. 3,177,114, dated Apr. 18, 2024, in 5 pages. [cited by applicant]
Examination Report in Australian application No. 2021263932, dated Jul. 3, 2024, in 4 pages. [cited by applicant]
Office Action received in Japanese application No. 2022-564505, dated Jun. 30, 2025. [cited by applicant]
Search Report and Written Opinion in Singapore application No. 11202254428S, dated Jul. 11, 2025, in 10 pages. [cited by applicant]